Gilead price target raised to $80 from $69 at Baird

Baird analyst Brian Skorney raised the firm’s price target on Gilead to $80 from $69 and keeps a Neutral rating on the shares. The analyst said Gilead put up a strong finish to the year as HIV continues to grow, while retaining its dominance and despite concerns on the cost of getting there, Gilead’s oncology sales provide a material source of revenue.